Cellectar Biosciences develops proprietary oncology drugs built around its Phospholipid Drug Conjugate™ (PDC) delivery platform. News about CLRB commonly centers on targeted radiotherapeutic programs, including iopofosine I 131 for Waldenström macroglobulinemia and CLR 121125, also called CLR 125, an iodine-125 Auger-emitting program for solid tumors such as triple negative breast, lung and colorectal cancers.
Company updates also cover clinical data from the CLOVER WaM study, oncology conference presentations, European and U.S. regulatory interactions, intellectual property protection, securities financings, and periodic financial results with corporate updates. The recurring disclosures reflect a late-stage clinical biopharmaceutical company funding and advancing cancer-cell-targeting treatments through internal development and research collaborations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) reported financial results for the year ended December 31, 2022, highlighting a net loss of $28.6 million, or $4.05 per share, compared to a net loss of $24.1 million, or $4.35 per share, in 2021. The company held cash and equivalents of $19.9 million, down from $35.7 million in 2021, with a net cash usage of approximately $25.2 million. R&D expenses rose to $19.2 million from $17.6 million, while G&A expenses increased to $9.5 million from $6.5 million. Notably, the company presented positive clinical data from ongoing trials and announced key leadership appointments, strengthening its commercial strategy in hematology and oncology.
On March 8, 2023, Cellectar Biosciences (NASDAQ: CLRB) announced its participation in two upcoming investor conferences. The Roth Capital Partners 35th Annual Conference will take place on March 13, 2023, featuring a fireside chat from 8:30 to 8:55 AM ET. The Oppenheimer 33rd Annual Healthcare Conference is scheduled for March 14, 2023, with a virtual presentation from 10:00 to 10:30 AM ET. Both events will include opportunities for one-on-one meetings with investors. Cellectar's focus is on developing cancer-targeting drugs, including its lead product, iopofosine, undergoing pivotal studies for various cancers.